Efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy compared with endoscopic ultrasound-guided gallbladder drainage for palliation of malignant distal biliary obstruction: a systematic review and meta-analysis.

Gastrointest EndoscMar 3, 2026 (epub)
Clinical ResearchGastroenterology

Saurabh Chandan, Tareq Alsaleh, Douglas G Adler

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) with gallbladder drainage (EUS-GBD) for palliation of malignant distal biliary obstruction when ERCP is not feasible or has failed. Five studies included 352 patients. Technical success was 93.3% with EUS-CDS and 95.9% with EUS-GBD (RR, 1.02; 95% CI, 0.94-1.10; P = .6). The analysis found no significant differences between techniques in clinical success, overall or severe adverse events, or stent dysfunction.

Key findings

  • Technical success was 93.3% with EUS-CDS and 95.9% with EUS-GBD (RR, 1.02; 95% CI, 0.94-1.10; P = .6).
  • Clinical success was 90.1% versus 86.6%, respectively (RR, 0.97; 95% CI, 0.90-1.05; P = .4).
  • Overall adverse events occurred in 19.7% with EUS-CDS and 17.6% with EUS-GBD (RR, 0.93; 95% CI, 0.58-1.48; P = .8).
  • Stent dysfunction was 15.0% with EUS-CDS and 14.5% with EUS-GBD (RR, 0.95; 95% CI, 0.35-2.58; P = .9).

Why it matters

For malignant distal biliary obstruction requiring palliation when ERCP cannot be performed or has failed, these pooled findings suggest both EUS-guided approaches can achieve high technical and clinical success. The absence of detected differences across key outcomes helps frame the options, while the evidence does not establish that the procedures are equivalent or that one should routinely be preferred.

What to keep in mind

The meta-analysis included only five studies, and the authors state that further prospective studies are needed to corroborate the findings.

Source

Published in Gastrointest Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.